All In Biotech

Investigational drug · Phase 2

UCB0022

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease.

Phase 2

Last checked: Nov 19, 2026Latest source record: Apr 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

4

Any phase or sponsor naming "UCB0022"

First trial start

2023

Nov 17, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "UCB0022", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Parkinson Disease

Approved drugs for the same conditions: Parkinson's disease · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "UCB0022" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Parkinson Disease

  • RadotinibSupect, IY5511Phase 33 trials

    Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory

  • CVN424Phase 32 trials

    Cerevance · Parkinson Disease, Parkinson's Disease

  • BHV-8000Phase 31 trial

    Biohaven Therapeutics Ltd. · Parkinson Disease

  • Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials

    iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)

  • AB-1005Phase 22 trials

    AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease

  • DNL151BIIB122Phase 22 trials

    Denali Therapeutics Inc. · Parkinson Disease

  • HBI-002Phase 22 trials

    Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell

  • VutiglabridinHSG4112Phase 22 trials

    Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from UCB.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.